As of October 23, 2026, altcoins represent about 42.62% of the $2.86 trillion crypto market, with Ethereum leading at $293.4 billion. However, over a quarter of this altcoin market consists of stablecoins and wrapped tokens, which do not act as true alternatives to Bitcoin. This distinction affects how investors interpret Bitcoin dominance and market shifts. Investors should carefully consider altcoin types, tax implications, and trading risks, especially given the large number of small, illiquid projects and regulatory nuances in Germany and the EU.
Altcoins market overview provides context for readers. As of Oct 24, 2026 01:31 WIB, 43 of 50 major cryptocurrencies on Pluang rose, 6 fell. Notable movers include LUNC at Rp0,841 (+3.57%, 195 days hold, 24% Sell / 76% Buy), YFI at Rp39.837.602 (+3.00%, 94 days hold, 33% Sell / 67% Buy), and UNI at Rp129.204 (+2.60%, 65 days hold, 52% Sell / 48% Buy).
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
